FDA Approves New Ulcerative Colitis Medication

April 5, 2013

The United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The Company released and marketed the product as DELZICOL™ (mesalamine) 400 mg delayed-release capsules.

DELZICOL (mesalamine) delayed-release capsules are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis. For information on dosage and administration, contraindications, warnings and precautions, adverse reactions, and other important safety and other prescribing information see http://www.wcrx.com/pdfs/pi/pi_delzicol.pdf.

The Company
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, primarily in North America. We are a fully integrated company with internal resources dedicated to the development, manufacture and promotion of our products.